|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Viropro Inc. (VPRO) to Unlock Value from its Biosimilars Portfolio; Creates a Biosimilars Technology Subsidiary in Canada
5/16/2012 10:00:22 AM
IRVINE, Calif.--(BUSINESS WIRE)--VIROPRO (VPRO.PK). Viropro, Inc. creates a technology subsidiary to focus on the burgeoning International market for biosimilar drug therapeutics. Over the past year, several of the large pharmas have tied up with Contract Research Organizations (CROs) and/or with Contract Manufacturing Organizations (CMOs) to enter the field of biosimilars. With the US FDA publishing guidelines for biosimilar approvals earlier this year, and guidelines already in existence in the European Union, this activity has taken a leap forward as companies jostle for position to capture parts of what is expected to be lucrative, multi-billion dollar annuities for years to come. According to a Frost & Sullivan report (PharmaTimes, U.K., May 11, 2012), the European biosimilars market is forecast to grow to $3.99 billion in 2017 from $172 million in 2010. That is equivalent to compound growth of 56.7% a year. The expiration of patents for blockbuster biologics is expected to drive the growth.
|
|
|
|
|
|
|
|
|
|
|